Relay Therapeutics, Inc. (RLAY) stock forecast and price target
Price $18.09 · data as of November 13, 2026
12-month price target
Average target$28.25
Upside / downside+56.2%
Analysts12
ConsensusStrong buy
Low $25.00Average $28.25High $32.00
Gold marker: average target · white marker: today’s price ($18.09)
Analyst ratings
Strong buy 3Buy 9Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.56 | +3.4% | $7M |
| Next fiscal year ends December 31, 2027 | $-1.57 | −1.0% | $11M |
| Next quarter ends December 31, 2026 | $-0.35 | −14.2% | $6M |
| Quarter after ends March 31, 2027 | $-0.38 | +6.4% | $720000 |
Consensus of the analysts covering Relay Therapeutics, updated daily. In the last 30 days 4 estimates were raised and 1 lowered.
Frequently asked questions
What is the Relay Therapeutics stock price target?
The average 12-month target from 12 analysts is $28.25, 56.2% above the current price of $18.09 Targets range from $25.00 to $32.00.
Is Relay Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 9 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Relay Therapeutics expected to earn?
Analysts expect EPS of $-1.56 for the fiscal year ending December 31, 2026 and $-1.57 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.